SCHEMBL4724629

SCHEMBL4724629

CCN1CCN(c2ccc(-c3nc(N)cc(NC)n3)cc2)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.50
RAD52 P43351 2/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
KDM4E B2RXH2 1/20 0.50
MAPT P10636 1/20 0.50
GFER P55789 1/20 0.50
ACHE P22303 1/20 0.43
FLT3 P36888 2/20 0.43
HDAC1 Q13547 1/20 0.43
CHRNA7 P36544 1/20 0.42
PIK3CA P42336 1/20 0.41
TLR9 Q9NR96 1/20 0.41
KDM1A O60341 1/20 0.40
ADRA2A P08913 1/20 0.40
ADRA2B P18089 1/20 0.40
ADRA2C P18825 1/20 0.40
FGFR1 P11362 1/20 0.40
FGFR2 P21802 1/20 0.40
JAK2 O60674 1/20 0.40
ADORA2A P29274 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20816284 0.80 GAA (0.52) GAARAD52SMN1; SMN2KDM4EMAPT
SCHEMBL18398034 0.79 ABCG2 (0.58) RAD52CHRNA7KDM1AADRA2AADRA2B
SCHEMBL5162476 0.79 GAA (0.61) GAARAD52SMN1; SMN2KDM4EMAPT
SCHEMBL16654067 0.79 LMNA (0.42) GAARAD52SMN1; SMN2KDM4EMAPT
SCHEMBL5176291 0.73 KDM4E (0.56) GAASMN1; SMN2KDM4EMAPTGFER
SCHEMBL18398025 0.72 GAA (0.46) GAARAD52SMN1; SMN2KDM4EMAPT
SCHEMBL20837413 0.71 KDM1A (0.51) GAARAD52SMN1; SMN2KDM4EMAPT
SCHEMBL373634 0.70 HCK (0.56) GAARAD52SMN1; SMN2KDM4EMAPT
SCHEMBL2377742 0.69 RAD52 (0.62) GAARAD52SMN1; SMN2KDM4EMAPT
SCHEMBL2177144 0.69 DYRK1A (0.50) KDM4ECHRNA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10624897-B2 Chlorobenzene substituted azaaryl compounds TAIPEI MEDICAL UNIVERSITY (TW) 2020-04-21 US disclosed
US-20190083499-A1 CHLOROBENZENE SUBSTITUTED AZAARYL COMPOUNDS TAIPEI MEDICAL UNIVERSITY (TW) 2019-03-21 US disclosed
EP-1976847-A2 PYRIMIDINYL ARYL UREA DERIVATIVES BEING FGF INHIBITORS Novartis AG (CH) 2008-10-08 EP disclosed
WO-2007071752-A2 PYRIMIDINYL ARYL UREA DERIVATIVES BEING FGF INHIBITORS NOVARTIS AG (CH) 2007-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10624897-B2 Chlorobenzene substituted azaaryl compounds MKI67, CTCF, CDKN1A GAA 1571/4885RAD52 1236/4885SMN1; SMN2 4690/4885
US-20190083499-A1 CHLOROBENZENE SUBSTITUTED AZAARYL COMPOUNDS MKI67, CTCF, CDKN1A GAA 1571/4885RAD52 1236/4885SMN1; SMN2 4690/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.